Abstract
This month’s article covers the period 16 April–15 May 2011. On 9 May it was announced that two of the most well-established and successful names in the field of drug delivery, Alkermes, Inc. and Élan Drug Technologies (ÉDT), the drug delivery division of the Élan Corporation, plan to merge. The sale of ÉDT was unsurprising as Élan had long been looking for a buyer. The merger with Alkermes to form a new company, Alkermes plc, sees the fusion of two institutions that emerged from the upsurge in drug-delivery research that occurred during the last three and a half decades of the 20th century. The focus of the new Alkermes will be on CNS diseases, an area that fits well to both companies’ existing portfolios. In the joint press release it states that Alkermes plc will focus on investing in an innovative pipeline of proprietary drugs. However, it is my hope that, given the history and expertise of Alkermes, Inc. and ÉDT, that the new company will also have enough money to invest in new technologies and the creation and development of the delivery systems of tomorrow. This Industry Update is mainly sourced from press releases and company websites.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
